Adult T-Cell Leukemia Overview

Save information for later
Sign Up

Learn About Adult T-Cell Leukemia

View Main Condition: Leukemia

What is the definition of Adult T-Cell Leukemia?
Adult T-cell leukemia/lymphoma (ATL) is is a rare and aggressive T-cell lymphoma that is linked to infection by the human T-cell lymphotropic virus 1 (HTLV-1). The exact mechanism by which HTLV-I infection causes the ATL is unknown. The clinical features of ATL include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as 'holes' on a standard bone x-ray), and skin lesions. There are four basic clinical variants of ATL: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases).
What are the alternative names for Adult T-Cell Leukemia?
  • Adult T-cell leukemia/lymphoma
  • ATLL
  • Adult T-cell leukaemia
  • Adult T-cell leukaemia/lymphoma (HTLV-1 positive)
  • Adult T-cell lymphoma
Who are the top Adult T-Cell Leukemia Local Doctors?
Elite in Adult T-Cell Leukemia
Dr. Thomas P. Loughran
Hematology Oncology | Oncology | Hematology
Elite in Adult T-Cell Leukemia
Dr. Thomas P. Loughran
Hematology Oncology | Oncology | Hematology

University Of Virginia Physicians Group

1215 Lee St, 
Charlottesville, VA 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Loughran is a Hematologist Oncology specialist and an Oncologist in Charlottesville, Virginia. Dr. Loughran is rated as an Elite provider by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Adult T-Cell Leukemia, Leukemia, Felty Syndrome, and Acute Myeloid Leukemia (AML). Dr. Loughran is currently accepting new patients.

Elite in Adult T-Cell Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology
Elite in Adult T-Cell Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia is rated as an Elite provider by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Masao Matsuoka
Elite in Adult T-Cell Leukemia
Masao Matsuoka
Elite in Adult T-Cell Leukemia
Masao Matsuoka
Kumamoto, JP 

Masao Matsuoka practices in Kumamoto, Japan. Mr. Matsuoka is rated as an Elite expert by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Adult T-Cell Leukemia, Leukemia, HTLV-1 Associated Myelopathy, Vitrectomy, and Trabeculectomy.

View All Doctors
What are the latest Adult T-Cell Leukemia Clinical Trials?
A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients With B Lineage Acute Lymphoblastic Leukemia
A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients With B Lineage Acute Lymphoblastic Leukemia
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to pre...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)
A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criter...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center